Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)2.60M
Market Cap
$380.13M
Enterprise Value$98.92M
Total Cash (Recent Filing)$26.36M
Total Debt (Recent Filing)$4.00M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Nov 06, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding60,530,140
10 Day Avg. Volume5,822,807
30 Day Avg. Volume2,598,000
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue136.19
Enterprise Value/Gross Profit-1.24K
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$15.20Price Target Upside148.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial DevelopmentsRecent $25M private placement and the agreement to study a combination of its drug with Lilly’s KRAS G12C in NSCLC show promising developments for the company.
Stock PotentialThere is significant upside potential in the stock at current levels, ahead of its data for the Ph 2a study of atebimetinib + GnP in 1L PDAC.
Strategic PartnershipsThe announcement of a new clinical supply agreement with Lilly for evaluating a combination therapy in certain NSCLC patients significantly boosted the stock.
Bears Say
Clinical Trial DelaysOther atebimetinib clinical trial combination arms are now expected to initiate in 2026 instead of the previously planned 2025.
Earnings PerformanceThe company reported an earnings per share of -$0.40, which is mostly in line with the consensus of -$0.42.
Safety ConcernsThe safety profile deteriorated slightly with higher percentages of neutropenia, anemia, and fatigue.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $380.13M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 13, 2025. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.41.
How many shares outstanding does Immuneering have?
Immuneering has 60,530,140 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went down -5.59%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at 0.
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.20 (148.77% Upside)
$15.20 (148.77% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $152.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.5%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.25%
12-Months-Change
Fundamentals
Return on Equity
-130.47%
Trailing 12-Months
Asset Growth
-48.04%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corporation (IMRX) is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of cancer and other diseases. The company's approach is centered around its proprietary platform that harnesses computational biology to unravel complex biological data and identify potential therapeutic targets. Immuneering aims to advance precision medicine by creating effective treatments that can precisely target specific disease pathways, offering new hope for patients with unmet medical needs.
IMRX Stock 12 Month Forecast
Average Price Target
$15.20
▲(148.77% Upside)
Technical Analysis
Bluebird Bio
―
Adicet Bio
―
Precision BioSciences
―
MAIA Biotechnology, Inc.
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
14.46% Insiders
3.39% Mutual Funds
1.17% Other Institutional Investors
78.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---